Co-infection and ICU-acquired infection in COVID-19 ICU patients: a secondary analysis of the UNITE-COVID data set

Andrew Conway Morris1,2,3†, Katharina Kohler1†, Thomas De Corte4,5†, Ari Ercole1,6†, Harm-Jan De Grooth7,8, Paul W. G. Elbers7, Pedro Povoas9,10,11, Rui Morais11, Despoina Kouentzi12,13, Sameer Jog14, Nathan Nielsen15, Alasdair Jubb1,6, Maurizio Cecconi16†, Jan De Waele4,5† and for the ESICM UNITE COVID investigators

Abstract

Background: The COVID-19 pandemic presented major challenges for critical care facilities worldwide. Infections which develop alongside or subsequent to viral pneumonitis are a challenge under sporadic and pandemic conditions; however, data have suggested that patterns of these differ between COVID-19 and other viral pneumonitides. This secondary analysis aimed to explore patterns of co-infection and intensive care unit-acquired infections (ICU-AI) and the relationship to use of corticosteroids in a large, international cohort of critically ill COVID-19 patients.

Methods: This is a multicenter, international, observational study, including adult patients with PCR-confirmed COVID-19 diagnosis admitted to ICUs at the peak of wave one of COVID-19 (February 15th to May 15th, 2020). Data collected included investigator-assessed co-infection at ICU admission, infection acquired in ICU, infection with multi-drug resistant organisms (MDRO) and antibiotic use. Frequencies were compared by Pearson's Chi-squared and continuous variables by Mann–Whitney U test. Propensity score matching for variables associated with ICU-acquired infection was undertaken using R library MatchIT using the “full” matching method.

Results: Data were available from 4994 patients. Bacterial co-infection at admission was detected in 716 patients (14%), whilst 85% of patients received antibiotics at that stage. ICU-AI developed in 2715 (54%). The most common ICU-AI was bacterial pneumonia (44% of infections), whilst 9% of patients developed fungal pneumonia; 25% of infections involved MDRO. Patients developing infections in ICU had greater antimicrobial exposure than those without such infections. Incident density (ICU-AI per 1000 ICU days) was in considerable excess of reports from pre-pandemic surveillance. Corticosteroid use was heterogenous between ICUs. In univariate analysis, 58% of patients receiving...
corticosteroids and 43% of those not receiving steroids developed ICU-AI. Adjusting for potential confounders in the propensity-matched cohort, 71% of patients receiving corticosteroids developed ICU-AI vs 52% of those not receiving corticosteroids. Duration of corticosteroid therapy was also associated with development of ICU-AI and infection with an MDRO.

**Conclusions:** In patients with severe COVID-19 in the first wave, co-infection at admission to ICU was relatively rare but antibiotic use was in substantial excess to that indication. ICU-AI were common and were significantly associated with use of corticosteroids.

**Trial registration** ClinicalTrials.gov: NCT04836065 (retrospectively registered April 8th 2021).

### Graphical abstract

Co-infection and ICU-acquired infection (UNITE-COVID)

- **Cohort:** 4994 patients admitted to 280 ICUs with COVID-19
- **54% developed ICU-acquired infection**
  - Bacterial pneumonia (44%)
  - Fungal pneumonia (9%)
  - Blood stream infection (15%)
  - Catheter-related infection (12%)
  - Urinary tract infection (12%)
- **MDRO 25% of all infections**

On admission:
- 14% with bacterial co-infection
- 85% received antibiotics

Corticosteroids strongly associated with prevalence of ICU-acquired infection even after adjustment for potential confounders with propensity matching.

- **Unadjusted**
  - 58% with steroids developed infection
- **Propensity score matched**
  - 71% with steroids developed infection

46% without steroids developed infection

52% without steroids developed infection

**MDRO - multi-drug resistant organisms**

**ICU - intensive care unit**

**COVID-19 - coronavirus disease 19**

Image made with BioRender.com

---

### Background

The Coronavirus Disease 2019 (COVID-19) pandemic has led to heightened rates of critical illness and has placed intensive care units (ICU) under unprecedented strain [1]. Although mortality has improved [2, 3], patients continue to experience prolonged admissions to ICU and organ support.

A notable feature critical illness arising from COVID-19 has been the high reported rates of ICU-acquired infections (ICU-AI), most notably ventilator-associated pneumonia (VAP) [4–6] and invasive pulmonary aspergillosis [7, 8]. VAP rates of 40–70% of ventilated patients exceed rates amongst contemporaneous non-COVID-19 patients [4] and historic comparators with influenza [6]. Reported COVID-associated pulmonary aspergillosis (CAPA) rates vary, are likely to be susceptible to the surveillance criteria used [7], but approach those reported for influenza-associated aspergillosis [9] and indeed amongst non-neutropaenic patients with VAP [10]. Other fungal infections such as Mucor mycosis have also been identified [11]. Other ICU-AI, including primary and catheter-associated bacteraemias and urinary tract infections, have been subjected to less attention, but also show elevated prevalence [12, 13]. The use of immunomodulatory therapies in patients with COVID-19 has been widespread, even before definitive evidence was available from randomised trials [14].

Whilst ICU-AI appear to be highly prevalent, exceeding those seen in patients with other viral pneumonias [6], co-infection at presentation appears to be rare [15, 16], reportedly in the range of 3–8%. This differs from influenza where bacterial co-infection is common [17, 18] and mortality is frequently attributed to these co-infecting organisms [19]. Influenced by the experience of influenza and the anticipated risk of co-infection, initial guidelines advocated the use of early broad-spectrum antimicrobials in patients with severe COVID-19 disease [20].
Methods

This study is a sub-analysis of the EXCM-UNITE-COVID study, which was an observational study carried out in 280 hospitals from 46 countries during wave one (defined as 1st of February until 15th of May 2020). Patients who were under intensive care on the day with the highest number of such patients during wave one were included in this analysis. The combined highest category was used as it was defined as 𝑝 < 0.05.

Details of the data collection methods, the collected data, and the data curation and DAQCORD-checklist are contained in the primary paper [1]. Briefly, UNITE-COVID is a multicenter, international, anonymized observational study carried out in 280 hospitals in 46 countries over 5 continents during the first wave of COVID-19. In this paper, we investigate factors associated with ICU-AI among intensive care patients admitted to critical care units across 280 units in 46 countries over 5 continents during the first wave of COVID-19.

This paper aims to describe the nature of co-infections, ICU-AI, and the development of antimicrobial resistance (AMS) were followed throughout this manuscript. The incidence of AMS was significantly higher in patients with ICU-AI compared with patients without ICU-AI. To adjust for the pre-defined confounders in our analysis we pre-defined factors thought likely to be associated with ICU-AI, namely age, sex, aggregate comorbidity severity score, duration of respiratory failure, and severity of respiratory failure. We defined ICU-AI as having a diagnosis of COVID-19 but documented SARS-CoV-2 infection with antibiotic use data collected until day 30 after admission. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for reporting observational studies in combination with the STROBE-AMS were followed throughout this manuscript. The Statistical analysis was performed using R Statistical Software (R: A language and environment for statistical computing; R Foundation for Statistical Computing, Vienna, Austria, 4.0.3).

Statistical significance was assessed using an ordinal scale of maximum improvement in antimicrobial stewardship (STROBE-AMS) were followed throughout this manuscript. The Mann–Whitney 𝑈 test was used for comparison of non-normally distributed continuous variables with categorical variables were calculated using a Pearson chi-squared test. The Mann–Whitney 𝑈 test was used for comparison of non-normally distributed continuous variables with categorical variables were calculated using a Pearson chi-squared test. The Mann–Whitney 𝑈 test was used for comparison of non-normally distributed continuous variables with categorical variables were calculated using a Pearson chi-squared test. The Mann–Whitney 𝑈 test was used for comparison of non-normally distributed continuous variables.
multiple fields of interest were excluded, where data were missing from one field multiple chained imputation (R library MICE [25]) was employed. We used a 1-to-1 matching of treated to controls in all the analysis except for the tocilizumab treatment analysis where the low number of treated patients allowed a ratio of one treated to three controls without losing match accuracy (Additional file 2: Model Formula S1). Initial analysis excluded those with respiratory co-infection on admission, with inclusion of these patients in a sensitivity analysis.

**Results**

Data were available from 4994 patients; demographic and clinical features of these patients have been described previously [1]. Overall 4129 (83%) were mechanically ventilated during their ICU stay, 2325 (47%) within 24 h of admission, whilst a further 1677 (34%) were ventilated later in their stay.

**Co-infection**

Bacterial pulmonary co-infection was detected in 716 patients (14%). Despite this, antibiotics were administered to 85% of patients. The immunomodulatory azithromycin made up 19% of all antibacterials, with 35% of all patients being prescribed this drug (Additional file 2: Table S1). Intubation at admission was associated with a significantly greater rate of antibiotic prescription (90% vs 86%, \( p = 0.0014 \)), as was suspicion of co-infection (98% vs 86%, \( p < 0.001 \)). 6% of patients received antifungals at admission (Additional file 2: Table S2). Patients with co-infection at ICU admission had similar pre-ICU hospital length of stay, a median of 1 day (IQR 0–4) with co-infection vs 2 days (IQR 0–4) for those without co-infection (\( p = 0.06 \)).

A comparison of inflammatory parameters between those with and without assessed co-infection at admission is shown in Fig. 1. Although several achieved statistically significant differences, there was substantial overlap between the groups.

**ICU-acquired infections**

ICU-AI were common, with 2715 (54%) patients developing a total of 4737 infections (median 2 infections per patient infected). The most common infection was bacterial pneumonia (reported in 77% of patients developing infections), followed by non-catheter-associated bacteraemia (seen in 26% of patients that developed an infection). Fungal respiratory infections were identified in 9% of all patients, and 16% of that developed an infection (Table 1). Of the patients with infection, 25% had an infection with an MDRO. The most prevalent MDRO’s were extended spectrum beta-lactamase producers (ESBL) (7.75%) and Methicillin-resistant *Staphylococcus aureus* (MRSA) (4.75%) (Additional file 2: Table S3).

Patients received a significant burden of antibiotic exposure during their admission, with a median 7 (IQR 0–17) days alive without antibiotics during the 30-day follow-up. The development of ICU-AI was associated with greater use of antibiotics; a median of 5 (IQR 0–14) antibiotic-free days in those with ICU-AI vs a median of 12 (IQR 0–23) in those without infection.

**Factors associated with ICU-AI**

Factors evaluated for association with ICU-AI are shown in Table 2. ICU-AI was associated with longer ICU length of stay (median 24 days (IQR 16–35) days vs 11 days (IQR 6–17) \( p < 0.001 \), as was infection with MDRO (29 days (IQR 19–43) days for MDRO vs 23 days (IQR 15–33) for those with non-MDRO infection \( p < 0.001 \)).

Receipt of antibiotics at admission was associated with development of subsequent infection (58% vs 46% of those not receiving antibiotics, \( p < 0.001 \)), but was not significantly associated with development of MDRO infection (24% vs 20%, \( p = 0.2 \)). Fewer antimicrobial-free days were associated with a higher prevalence of MDRO infection (median antimicrobial-free days 2 (IQR 0–9) for patients with an MDRO infection vs 6 days (IQR 0–15) for patients without an MDRO infection, \( p < 0.01 \)). Corticosteroid use was higher amongst patients developing infection in ICU (58% vs 43%). Steroid use was heterogeneous across centres (Fig. 2) with the dominant indications being hyperinflammation and pneumonitis, which together made up 65% of indications recorded (Additional file 2: Table S4). Shock was the indication in 16% of cases.

**Propensity-matched analysis.**

Following the finding of an increased risk of infection amongst patients receiving corticosteroids in univariate analysis, we undertook a propensity-matched analysis to further understand this relationship, undertaking matching for pre-defined factors thought to be associated with infection (Table 2). Heterogeneity of steroid use between units extended to both the percentage of patients receiving steroids in each centre and the duration of therapy (Fig. 2). Additional file 2: Fig. S1 shows the selection of the matched cohort. Using 1:1 matching, 1086 were entered into this analysis, and matching was highly effective (Fig. 3), with absolute standardised mean differences after matching all less than 0.1. The calculated pseudo-\( R^2 \) was 0.33 (details in Additional file 2).

In the matched cohort, the relationship between steroids and infection was maintained: 71% of those receiving steroids developed ICU-AI vs 52% of those not in receipt
of steroids ($p<0.001$). The main indications for steroids in the propensity-matched cohort were hyper-inflammation and shock (Additional file 2: Table S5). Steroid use was also associated with MDRO infections (17% of infections in patients on steroids were with MDRO organisms, vs 5% of those not on steroids ($p<0.001$). Duration of steroid administration was also associated with ICU-AI in this analysis, with those developing ICU-AI receiving steroids for a median of 8 days (IQR 3–14) vs 5 days (IQR 3–10) for those not developing infection. The median time spent in ICU before steroid administration was 2 days (IQR 0–8) in patients who did not develop an infection in ICU and 6 days (IQR 1–13) in those who did. The mortality rate was higher in the steroid treatment cohort with 37% compared to 30% in the non-steroid cohort ($p=0.02$).

As a sensitivity analysis, inclusion of those who had co-infection on admission did not significantly alter the results of the propensity-matched analysis (Additional file 2: results).
Rates of tocilizumab use were much lower than corticosteroids, with only 132 patients receiving this. In a 1:1 match using the same matching variables and matching method, tocilizumab use was not associated with an increase in the risk of ICU-AI: 56% of patients without tocilizumab developed infection vs 46% of those receiving this agent \( (p = 0.04) \). Details of the matching are shown in Additional file 2: Figs. S2 and S3.

### Discussion

This study describes the largest ICU cohort with COVID-19 so far reported and covers patients from a wide range of countries. The rate of co-infection, at 14%, is above the 3–10% reported in other studies \([15, 16, 18, 26]\) including those that were restricted to critically ill patients \([26]\). Although there was a marginal effect of co-infection on the use of antibiotics at admission, the great majority of patients received antibiotics despite the absence of assessed co-infection. At the time of data collection, guidelines indicated that broad spectrum antibiotics should be administered to all patients with severe disease \([20]\).

The finding of high rates of ICU-AI, with over half of all patients developing such infections, is consistent with previous reports from critically ill COVID-19 patients which have largely focussed on ventilator-associated pneumonia \([4–6]\), and bacteraemia \([12, 13]\), notably also the predominant infections encountered in this cohort.

Whilst debate continues regarding the true incidence of CAPA \([27, 28]\), in this study we found fungal pulmonary infections complicated the stay of 9% of all patients. This is a lower prevalence than some reports \([8]\), but may reflect underdiagnosis as at the time of data collection CAPA was a novel diagnosis \([7]\). The rate of ICU-AI reported far-exceeds pre-pandemic rates reported by the European Centres for Disease Control (ECDC) \([29]\). In 2017, ECDC reported rates of ICU-acquired infection were 8.3% for all patients staying more than 2 days in ICU, with pneumonia complicating 6% of stays, bloodstream infections (BSI) 4% and urinary tract infections (UTI) 2% \([29]\). Whilst diagnostic uncertainty caused by tracheal colonisation and viral pneumonitis may confound the incidence of ICU-acquired pneumonia, such uncertainty is unlikely to be present with infections at other sites. Studies from multiple units which have used rigorous diagnostic criteria have found a similarly high rate of bacterial pneumonia \([4–6]\) reporting prevalences of 44 to 50%. We cannot be certain that some identified

| Table 1 Description of ICU-acquired infections identified in patients |
|---------------------------------------------------------------|
| **Site/class of infection** | **N (% of all infections)** | **Rate per 1000 ICU days** |
| Bacterial pulmonary infection | 2091 (44%) | 22.2/1000 ICU days |
| Fungal pulmonary infection | 447 (9%) | 4.7/1000 ICU days |
| Bacteraemia (not catheter related) | 708 (15%) | 7.5/1000 ICU days |
| Catheter/line-associated blood stream infection | 563 (12%) | 6/1000 ICU days |
| Urinary tract infection | 572 (12%) | 6.1/1000 ICU days |
| Abdominal infection | 88 (2%) | 0.9/1000 ICU days |
| Central nervous system infection | 20 (0.4%) | 0.2/1000 ICU days |
| Other ICU-acquired infection | 248 (5%) | 2.6/1000 ICU days |

*Rate per 1000 ICU days only includes patients with value for length of stay—459 (9%) patients were not included in the rate calculation

| Table 2 Demographic and clinical factors assessed for association with development of ICU-acquired infections, median (IQR) values shown for continuous and ordinal variables |
|---------------------------------------------------------------|
| **Parameter** | **ICU-acquired infection** | **No ICU-acquired infection** | **p value** |
| Age | 62 (54–70) | 62 (52–71) | 0.975 |
| Percentage male | 73% | 69% | 0.003 |
| Comorbidity score | 1 (0–2) | 1 (0–1) | 0.0004 |
| Percentage receiving steroid treatment | 58% | 43% | < 0.001 |
| Ventilation severity score | 3 (2–3) | 2 (1–3) | < 0.001 |
| Mechanically ventilated at any time | 97% | 72% | < 0.001 |
| Ventilation duration (days) | 21 (14–31) | 10 (6–15) | < 0.001 |
| Vasopressor/inotrope at any time | 50% | 25% | < 0.01 |
| Renal replacement therapy at any time | 18% | 6% | < 0.01 |
Fig. 2  Forest plot of steroid treatment by centre: Colour and dot size represent the percentage of overall patients that received steroid treatment, the forest plot shows the median and IQR of length of steroid treatment. Centres are ordered by the median length of time patients receive steroids.
Fig. 3 Propensity score (PS) matching for corticosteroid matching parameters compared to the input cohort. A density plots and histograms showing the effect of PS matching on distributions. B Covariance balance ‘love’ plot illustrating the effect of PS on standardised mean difference. C Numeric summary statistics following PS matching. Reporting percentages for categorical variables, mean for non-skewed parameters, and median for skewed parameters. Last two entries below the thick line are outcome measures and were not used for matching.
ICU-AIs were not, in-fact, missed co-infections, and this could influence the relationship between initial antibiotics and subsequent detected ICU-AI. However, previous studies of ICU-AI have shown clinicians can readily distinguish the two [30, 31]. This is unlikely to alter the results of our findings, as including patients with identified co-infection did not substantially alter the results from the propensity-score-matched analysis (Additional file 2: results). The high rate of secondary infection seen in this current cohort was reflected in associated exposure to antibiotics, and strikingly, a substantial proportion of antibiotic use was not targeted towards either co-infection or ICU-AI. MDRO were encountered in a quarter of all those developing ICU-AI, similar to the prevalence reported in other large surveys of infection in ICU [32]. The association between duration of antimicrobial therapy and development of MDROs may reflect the selective pressure of prolonged antimicrobial infection but may also reflect the perceived need for prolonged antimicrobial therapy in patients who develop MDRO infections.

The reasons for the high rates of ICU-AI amongst patients with COVID remain uncertain and cannot be completely explained by prolonged duration of organ support [4, 6]. The ECDC 2017 report notes median incident density of 3.7/1000 ICU days (IQR 0.8–4.9) for pneumonia, 1.9/1000 ICU days (IQR 0.4–3.1) for all BSIs and 2.4/1000 ICU days (IQR 0–3.7) for UTI [29]. The incident density shown in Table 1 is in considerable excess of these. In this study, we identified a significant association between the use of corticosteroids and the development of such infections and infections with MDRO, which was maintained after adjustment for potential confounders. As an observational study, however, we cannot exclude residual confounding as a cause of this association. In this study, corticosteroids were not associated with increased survival, so it is unlikely that their use increased infection due to patients surviving long enough to develop an infection in ICU. The finding of increased unadjusted mortality amongst patients receiving steroids may reflect differences between patients selected for corticosteroid therapy, although other reports have noted similar effects even after adjusting for clinical variables [33, 34].

The literature concerning the effect of corticosteroids on ICU-AIs is divergent, with reports of both increased [35] and decreased infection rates [36]. In the randomised trials examining the use of corticosteroids in COVID-19 [37–41] an association was not found with secondary infections. However, the largest of these studies [38, 41] did not specifically look for secondary infections. Two smaller studies [39, 40] reported no significant differences, although the overall rates of secondary infection were lower than those reported here and elsewhere in the literature [4–6, 12, 13]. Our study is observational, and so we cannot exclude unmeasured confounders. However, it reports data from ‘wave one’ before the announcement of the results of the landmark RECOVERY trial [38] and corticosteroid use varied markedly between centres (Fig. 2). Furthermore, a wide range of steroid doses and durations of therapy were deployed early in the pandemic. It may be that prolonged and high-dose courses of corticosteroids explain why our results diverge from those reported in clinical trials [39, 40]. Other observational studies have found a relationship between corticosteroid use and subsequent pneumonia in single centre [42] and multi-centre cohorts [34, 43], with the Dupuis and colleagues study noting a relationship between steroid dose and infection risk [34]. It is possible that steroids were prescribed because of secondary infection i.e. a reverse causal relationship, though we did not find an excess of shock amongst patients receiving steroids who developed secondary infection (Additional file 2: Table S5). It was, perhaps, surprising to find that tocilizumab was not associated with an increased risk of ICU-acquired infection and indeed the effect seen was in the opposite direction. We note a similar finding recently reported in a single centre study of catheter-related blood stream infections, where dexamethasone but not tocilizumab was associated with increased risk of infection [44]. It is possible that this finding resulted from failure to diagnose infection due to supressed inflammatory responses, most especially C-reactive protein and procalcitonin concentrations [45]. Alternatively, if tocilizumab was reserved for later in patient stays, it may have been withheld in patients in whom there was suspicion of secondary infection; however, lack of data on the relative timing of these events makes these hypotheses speculative.

This study has a number of strengths, among them that it is the largest study of critically ill patients with COVID-19 reported to date and provides data from a wide range of geographic locations and healthcare settings. However, the data collected were limited by the feasibility of collecting data from hundreds of geographically diverse sites during the early phase of the pandemic. As such we had to rely on investigator ascertainment of the presence of infection, which may not have been standard across sites and did not collect details of microbiological cultures beyond the presence or absence of specific MDROs. That the rates of ICU-AI were similar to those reported from smaller, but more rigorously controlled studies are reassuring [4–6, 11, 12], and patterns seen were similar across all infections, as well as the more objective measures of MDRO rates and antibiotic use. With widespread use of antibiotics noted, it is possible that these would mask the detection of ICU-AI and that the rates of ICU-AI are
actually higher than we report, although this is unlikely to alter the relationships seen with the therapeutic agents examined. We did not collect data on formulation or dose of corticosteroid used and therefore cannot assess the impact that variations in these may have had.

Conclusions

In conclusion, this study has demonstrated widespread use of antibiotics in critically ill patients during the first wave of COVID-19. Although this use may appear indiscriminate, their use at admission was in line with guidelines extend the time at which patient inclusion [20]. Admissions with bacterial co-infection were relatively rare, and there was significant potential to limit antibiotic use at this point. Although ICU-AI were common, driving antibiotic use, this use extended beyond patients with secondary infections, indicating potential for further reduction in antibiotic utilisation. The finding of an association between corticosteroid use and ICU-AI requires further exploration, as do strategies for infection diagnosis in the presence of concurrent anti-cytokine therapies.

Abbreviations

BSI: Blood stream infection; COVID-19: Coronavirus disease 19; CAPA: COVID-associated pulmonary aspergillosis; ECMO: Extra-corpooreal membrane oxygenation; ECDC: European Centres for Disease Control; ESBL: Extended spectrum beta-lactamase producers; ICU: Intensive care unit; ICU-AI: Intensive care unit-acquired infection; MDRO: Multi-drug resistant organisms; MRSA: Methicillin-resistant Staphylococcus aureus; SARS-CoV2: Severe Acute Respiratory Syndrome Coronavirus-2; STROBE: The Strengthening the Reporting of Observational Studies in Epidemiology; STROBE-AMS: The Strengthening the Reporting of Observational Studies in Epidemiology antimicrobial resistance and informing improvement in antimicrobial stewardship, UTr: Urinary tract infection; VAP: Ventilator-associated pneumonia.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13054-022-04108-8.

Additional file 1: Case report form. Additional file 2: Supplemental data.

Acknowledgements

We want to thank Guy Francois of the European Society of Intensive Care Medicine for his support. We thank the ESICM COVID UNITE National Coordinators for their help: Bangladesh: Tanjil Hamid; Belgium: Jan De Waele, Jean-Baptiste Mesland; Canada: Michael Sklar; Chile: Patricio Vargas; China: Bin Du; Colombia: Daniel Molano Franco; Estonia: Jüri Jõgisoo; France: Hervé Iracene; Germany: Karl Friedrich Kuhn; Greece: Ioanna Soultati; Hungary: Anna Bereczki; Iran: Salar Esmaeili; Italy: Aleandro Turani, Paul Andreuccetti; Japan: Jumpei Kawasaki; Korea: Sang-Gyu Kim; Malaysia: Eric Ho; Mexico: Luis Felipe Reyes; Netherlands: Johannes Laherm; Pakistan: Rana Ali Elbuzidi; Peru: Juan Luis Pinedo Portilla; Poland: Agata Zgierska; Portugal: Pedro Povoa; Russia: Vitaly Gusarov; Saudi Arabia: Yaseen Hashmi; Spain: com; Sweden: Henrik G. Gottfries; Switzerland: Rahmat pour Nour; Turkey: Arzu Topeli; United Kingdom: Alasdair Jubb; United States: Nathan D. Nielsen. The full list of ESICM UNITE COVID authors is noted below.

The ESICM UNITE COVID study group members

argentina: Hospital de Agudos Santojanni (Buenos Aires): Marco Bezzì; Hospital Universitario Austral (Buenos Aires): Alicia Gira; AUSTRIA: Medical University of Graz (Graz): Philipp Eller; BANGLADESH: Asgar Ali Hospital (Dhaka): Tanjil Hamid; Central Police Hospital (Dhaka): Injamam Ul Haque; BELGIUM: AZ Rivierenland (Borgerhout): Wim De Buyer; CHIRIEC Hospitals (Brussels): Antonella Cudia, Daniel De Backer, Pierre Poulon; Cliniques de l’Europe, St-Michel (Brussels): Vincent Collin, Universitair Ziekenhuis Gent (Gent): Jan De Waele, Jolien Van Hecke, UZ Brussel (Jette): Elisabeth De Waele, Claire Malderen; CH Jolimont (La Louvière): Jean-Baptiste Mesland; CHU Charleroi (Lodelinsart): Michael Pagniennel, CHU Ambroise Pare (Mons): Lionel Haertens; Clinique Saint-Pierre (Ottignies): Nicolas De Schryver; GZA Ziekenhuizen (Wilrijk): Jolien Van Leemput, Philippe Vanhove, Mont-Godinne University Hospital, CHU UCL Namur (Yvoir): Pierre Bulp; BULGARIA: Multidisciplinary Hospital for Pulmonary Diseases St. Sofia (Sofia): Viktoria Ilieva; CANADA: Brampton Civic Hospital (Brampton): David Katz; North York General Hospital (Toronto): Anna Geaggea; William Oslor Health System—Etobicoke General Hospital (Toronto): Alexandra Binnie; CHILE: Complejo Asistencial Dr. Victor Rios Ruiz (Los Angeles): Fernando Tirapegui; Hospital Clinico Fusiat (Rancagua): Gustavo Lago, Clínica Alemana de Santiago (Santiago): Jerónimo Graf, Rodrigo Perez-Araos; Hospital del Salvador (Santiago): Patricia Vargas; Facultad de Medicina, Escuela de Medicina, Universidad Andes Bello (Viña del Mar): Felipe Martínez; Hospital Naval Almirante Buy (Viña del Mar): Eduardo Labarca; COLOMBIA: Hospital San Jose (Bogota): Daniel Molano Franco; Universidad de La Sabana (Chía) and Clínica Universidad de La Sabana (Chía): Daniela Parra-Tanoux, Luis Felipe Reyes; Ces Clinic (Medellín): David Yepes; CROATIA: University Hospital Split (Split): Filip Perić, Srdan Stojanovic Stipić; ECUADOR: Hospital General Guasmo Sur (Guayaquil): Cynthia Vanessa Campanozzo Burgos, Paulo Roberto Navas Boada; Hospital de Especialidades Porlamar (Portoviejo): Jose Luis Barberan Bru, Juan Pablo Paredes Ballesteros; EGYPT: Gamal Abdelvassil (Alexandria): Ahmed Hammouda; Wingat Royal Hospital (Alexandria): Omar Elmandouh; Luxor Pyretic Medical Centre (Armant): Ahmed Azzam, Assiut University Hospital (Assiut): Ailie Mohamed Hussein; Aswan University Hospital (Aswan): Islam Galal, Ain-Shams University Hospitals (Cairo): Ahmed K. Awad; Kasr Al Ainy Cairo University Hospital (Cairo): Mohamamed A Azab, Misr International Hospital (Cairo): Maged Abdalla, Behatallah Assal, Mostafa Alfishawy; El-Sheikh Zayed Specialized Hospital (Giza): Sherief Ghzy; Mansoura University Hospitals (Mansoura): Samar Thanwat, Elmenshawy General Hospital (Tanta): Abdullah Eldaly; ESTONIA: Tartu University Hospital (Tartu): Veronika Reinhard; FRANCE: Hôpital d’Instruction des Armées Percy (Clamart): Anne Christms, Chrystele Poyat; Hôpital Nord Franche-Comté (Trevannes): Julio Badie, Fernando Berlaquer Ferrari; GERMANY: Charité—Universitätsmedizin Berlin, ICU 8i (Berlin): Björn Weiss; Charité—Universitätsmedizin Berlin, ICU 43i (Berlin): Karl Friedrich Kuhn; Charité—Universitätsmedizin Berlin, ICU 44i (Berlin): Julius J. Grunow; Charité—Universitätsmedizin Berlin, ICU 144i (Berlin): Marco Lorenz; Charité—Universitätsmedizin Berlin, 203i (Berlin): Stefan Schaller; University Hospital Dresden (Dresden): Peter Spreth, Bethesda Krankenhaus Bergedorf (Hamburg): Marc Bota; University Hospital Leipzig (Leipzig): Falk Fichtner; Klinikum Rechts der Isar der TUM, 151i/M21 (Munich): Kristina Fuest; Klinikum Rechts der Isar der TUM, 39a (Munich): Tobias Lahmmer; University Hospital of Wurzburg (Wurzburg): Johannes Herrmann, Patrick Meybohm; GREECE: General Hospital of Eleusis ‘Thrasonis’ (Eleusis): Nikolaos Markou; George Papanikolaou General Hospital (Exoiti-Thessaloniki): Georgia Vasileiadou; University Hospital Attikon (Haidari): Evangelia Chrysanthopoulou; General Hospital of Larissa (Larissa): Panagiotis Papamichalis; University General Hospital of Thessaloniki AHEPA (Thessaloniki): Ioanna Soutati; INDIA: Deenanath Mangeshkar Hospital and Research Center (Pune): Sameer Jog; Tata Memorial Hospital, Homi Bhabha National University (Mumbai): Kushal Kalvit; Sheila Nainan Myatra; IRELAND: Cavan General Hospital (Cavan): Ivan Krupa; Our Lady of Lourdes Hospital (Drogheda): Aisa Thanwat, St Vincent’s University Hospital (Dublin): Alistair Nichol; Galway University Hospitals (Galway): Aine McCarthy; IRAN: Imam Reza Hospital (Tabriz): Arai Mahmoodpoor; ITALY: Sant’Orsola University Hospital (Bologna): Tommaso Tonetti; Santissima Trinita Hospital (Cagliari): Paolo Isoni, Arcispedale Sant’Anna (Ferrara): Savino Spadaro, Carlo Alberto Volta, University of Foggia OsPEDALI-riunits Foggia (Foggia): Lucia Mirabella, AUO G. Martino (Messina): Alberto Noto; Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico (Milan): Gaetano Florio, Amedeo Guzzardella, Chiara Paleari; IRCCS Humanitas Research Hospital (Milan):
Federica Baccaneli, Marzia Savi, Gemelli IRCCS (Rome): Massimo Antonelli, San Luca (Treviso Rovigo): Barbara Vaccarini; Città della Salute e della Scienza—Presidio Molinette (Turin): Giorgia Montrucchio, Gabriele Sales; University Hospital Integrated Trust (AOU) (Verona): Katia Donadello, Leonardo Grottin, Enrico Polati, San Bortolo Hospital (vicenza): Silvia De Rosa; KENVYA: MP Shah Hospital (Nairobi): Demet Sulemanli; LIBYA: Almwasaf Hospital (Tripoli): Abdurraouf Albasalama; Tripoli University Hospital (Tripoli): Mohamed Elhamad; MEXICO: Hospital General De Ecatepec Las Americas (Ecatepec de Morelos): Montelongo Felipe De Jesus; Hospital civil nuevo dr Juan I Menchaca (Gdlalajara): Dani Rodríguez González; Hospital de Especialidades Dr Antonio Fraga Muret CNLM La Raza (Mexico): Nancy Caneo, Alejandro Esquivel Chavez; MOROCCO: Ibn Sina University Hospital (Rabat): Tarek Dedane; NETHERLANDS: ziekenhuisgroep Twente (Almelo): Bart Grady, Ben de Jong; Amsterdam UMC, VUMC site (Amsterdam): Eveline von der Heiden, Patrick Thoari, Onze Leve Vrouwe Gasthuis (Amsterdam): Bas van den Bogaard; Gelre ziekenhuizen (Apeldoorn): Peter E. Spronk; Haaglanden Medisch Centrum (Den Haag): Sefanja Achterberg, Deventer ziekenhuis (Deventer): Melanie Groeneveld; Albert Schweitzer Hospital (Dordrecht): Rolf K.L. So, Calvin de Wijs, Catharina ziekenhuis (Eindhoven): Harm Scholten; Medisch Spectrum Twente (Enschede): Albertus Beshuizen, Alexander D. Cornet; Martini ziekenhuis (Groningen): Auke C. Reidinga; University Medical Center Groningen (Groningen): Henriette de Boer, Marcel de Groot; Tjongerschans Heereneven (Heereneven): Oliver Becker; Medical Centre Leeuwarden (Leeuwarden): Carina Bethelhem; Maastricht University Medical Center (Maastricht): Bas van Bussel; Radboudumc (Nijmegen): Tim Frenzel; Elisabeth TweeSteden ziekenhuis (E2Z) (Tilburg): Celeste de Jong, Rob Witting; University Medical Center Utrecht (Utrecht): Josef Keszeciovglu; VieCuri Medical Center (Venlo): Jannet Meihagoul-Schiper; NIGERIA: University of Port Harcourt Teaching Hospital (Port Harcourt): Doyonie Alasia; PAKISTAN: Ziauddin Hospital Clifton Campus (Karachi): Ashok Kumar; Bahria International Hospital (lahore): Aahad Qayyum, Muhammad Rana; PALESTINE: Alshifa Hospital (Gaza): Mustafa Abu Jayyab; PERU: Hospital Nacional Dos de Mayo (Lima): Rosario QuispeSierra; PHILIPPINES: Asian Hospital and Medical Center (Muntinlupa): Aaron Mark Hernandez; PORTUGAL: Hospital de Cascais—Dr. José de Almeida (Alcabideche): Lúcia Taborda, Hospital Prof. Dr. Fernando da Fonseca, E.P. (Amadora): Tiago Ramires, Centro Hospitalar e Universitário de Coimbra (Coimbra): Catarina Silva; Centro Hospitalar de Leiria (Leiria): Carolina Ranz; Hospital Sao Francisco Xavier (Lisboa): Pedro Póvoa; Hospital Beato Angelô (Loulés): Patricia Patricio; Centro Hospitalar e Universitário de São João, Infectious Diseases Intensive Care Unit (Porto): Maria Lurdes Santos; Centro Hospitalar Universitário de São João, Servico de Medicina Intensiva (Porto): Vasco Costa, Pedro Cunha; Centro Hospitalar Universitário do Porto, Hospital Santo Antonio (Porto): Celina Gonçalves; Centro Hospitalar de Entre o Douro e Vouga (Santa Maria da Feira): Ignacio Catalan-Monzon, Laura Galzar; Hospital Universitario de Getafe (Getafe): Fernando Frutos-Vivar, Jorge Jimenez; Carmen Rodriguez-Solis; Hospital San Jorge (Huesca): Enric Franquesa-Gonzalez; Complejo Hospitalario Insular Materno Infantil (Las Palmas de Gran Canaria): Guillermo Pérez Acosta, Luciano Santana Cabrera; Hospital Universitario Severo Ochoa (Leganes): Juan Pablo Alvari Arpa, Francisco Muñoz Monclus; Hospital General de Torrejón (Madrid): Maria Cruz Martin Delgado, Carlos Munoz de Cabo; Hospital Universitario Fundacion Jimenez Diaz (Madrid): Ana Maria Loin; Cesar Perez-Calvo, Arndlo Santos; Hospital Universitario Infanta Leonor (Madrid): Ana Abad-Motos, Javier Ropilones-Melchor; Hospital Universitario La Paz (Madrid): Belén Cavatos-Montesino, Santiago Yus-Terruel; Hospital Universitario Príncipe de Asturias (Madrid): Juan Higuera Lucas; Hospital Universitario Ramón y Cajal (Madrid): Aaron Blancho Ortiz, Raúl de Pablo Sánchez; Regional University Hospital of Malaga (Malaga): Jesús Emilio Barrueco-Francín; Hospital Universitario Central de Asturias (Oviedo): Lorena Forcelledo Espina, Hospital Quironsalud Palapalmapalan (Palma de Mallorca): Jose M. Bonell-Goity; Hospital Universitario Infanta Leonor (Madrid): Jose Angel Berdez-Bergo, Virginia Fraile; Hospital Universitario Rio Hortega, Servicio de Medicina Intensiva (Valladolid): José Angel Berdez-Bergo, Virginia Fraile; Hospital Universitario Rio Hortega, Servicio de Medicina Intensiva, Unidad 2 (Valladolid): Cristina Cuenca-Rubio, David Perez-Torres; Hospital Clinico Universitari de Valencia (Valencia): Ainhoa Serrano; Hospital Universitario de La Plana (Vila-Real): Clara Martinez Valero, Hospital Comarcal Vinaroz (Vinara): Andrea Ortiz Surer; Hospital Universitario de Alava (Vitoria-Gasteiz): Leire Lagaraga, Noemi Legaristi, Hospital Virgen de la Concha (Zamora): Gerardo Ferrigino; SWITZERLAND: Aalaa Specialist Hospital (Omdurman): Yousif Aljafari; University Hospital of Malaga (Malaga): Malvina Diamond Burns, Andrea Glotta; SWEDEN: Hallands Sjukhus (Halmstad): Frank Zoorzer, Karlolinska University Hospital (Huddinge): Jonathan Nip, Kristina Kilsand, Sunderby Hospital (Luleå): Jonas Österlind; Akademiska Sjukhuset (Uppsala): Magnus von Seth, Västerviks Sjukhus (Västervik): Jon Berkius; SWITZERLAND: Clinica Luganese Monucco (Lugano): Samuel Ceruti, Andrea Glattha.
TURKEY: Ankara City Hospital / General Hospital (Ankara); Seval Izedes; Ankara City Hospital Orthopedics and Neurology Hospital (Ankara); Işıl Özoğlan Turan; Gulhan Ergümve Arastirma Hastanesi (Ankara); Ahmet Cosar; Hacettepe University (Ankara); Burcu Halacli; University of Health Sciences Koceri Training and Research Hospital (Ankara); Necla Deger; Derinçez Research and Education Hospital, Health Sciences University (Derince / Koçaeli); Mehmet Yilmaz; Düzce University School of Medicine (Düzce); Turky Abdas; Gaziantep University (Gaziantep); Gülsen Eray; Giresun University Dept. Prof. Dr. A. İlhan Özdemir Eğitim Araştırması Hastanesi (Giresun); Selin Eyyüpoğlu; Kartal Dr. Lufti Kaidar Şehir Hastanesi (Istanbul); Yeliz Biliar; Kemal Tolga Saraçoğlu; SBU Kanuni Süleyman Education and Training Hospital (Istanbul); Ebru Kayar, Ayca Sultan Sahin; Ege University School of Medicine (İzmir); Pervin Korkmaz Ekren; Niğde Research and Training Hospital (Niğde); Tuğçe Mengi; Sakarya University Education Research Hospital (Sakarya); Kezban Ozmen سور; Yakuq Tomak; Kanuni Education and Training Hospital (Trabzon); Ahmet Erogulu;

UNITED ARAB EMIRATES: Mediclinic City Hospital (Dubai); Asad Alsababah; UNITED KINGDOM: Aberdeen Royal Infirmary (Aberdeen); Katie Hanlon; Belfast City Hospital (Belfast); Kevin Gervin, Sean McMahon; Ulster Hospital (Belfast); Samantha Hagan; Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust (Birmingham); Caroline V Higenbottam, Randeep Mulhiri; Lottie Poulton, Tomasz Torlinski; Royal Blackburn Hospital (Blackburn); Allen Garrett, Nick Truman; West Suffolk Hospital NHS Foundation Trust (Bury St Edmunds); Gopal Vijayakumar; Cambridge University Hospitals (Cambridge); Chris Hall, Alasdair Jubb; Royal Papworth Hospital NHS Foundation Trust (Cambridge); Lenka Cagova, Nicola Jones; Countess Of Chester (Chester); Sam Graham, Nicole Robin; Darlington Memorial Hospital (Darlington); Amanda Cowton; Altnagelvin Hospital—WhSCT (Derry); Adrian Donnelly; Doncaster Royal Infirmary (Doncaster); Natalia Singatullina; University Hospital of North Durham (Durham): Melanie Kent; Royal Devon & Exeter NHS Foundation Trust (Exeter); Carole Boulanger; Royal Surrey Hospital (Guildford); Zoe Campbell, Elizabeth Potter; Royal Great Western Hospital (Gwent); Natalie Duric, Tamas Szakmany; Harefield Hospital, Royal Brompton and Harefield NHS Foundation Trust (Harefield); Orinta Kvistikovska, Nandor Macsinz; The Princess Alexandra Hospital NHS Trust (Harlow); Caroline Ellis, Ragnhild Saha; Harrogate District Hospital (Harrogate); Chunha Sri-Chandana; NHS University Hospital Crosshouse (Kilmarnock); John Allan; Kingston Hospital (Kingston upon Thames); Lana Murnel, Harish VenkatEsh; University Hospitals of Morecambe Bay NHS Foundation Trust; Royal Lancaster Infirmary (Lancaster); Vera Nina Gotz; St Helens and Knowsley Teaching Hospitals NHS Trust (Liverpool); Anthony Cochrane; Guy’s & St Thomas’ Hospital (London); Nuttha Lumlertgul, Barbara Ficial; Homerston University Hospital NHS Foundation Trust (London); Susan Jain, Royal Brompton Hospital, Royal Brompton and Harefield NHS Foundation Trust (London); Giulia Beatrice Crapelli, Aikaterini Vlachou; Maidstone Hospital (Maidstone): David Golden; Borders General Hospital (Melrose): Sweny Garrioch, James Cook University (Middlesbrough); Jeremy Henning, Gupta Loveleena, The Tunbridge Wells Hospital (Pembury); Miriam Davie; Queen’s Hospital (Romford); Lina Grauslyte, Erika Salcute-Simene, Salisbury NHS Foundation Trust (Salisbury): Martin Cook, Stepping Hill Hospital (Stockport): Danny Barling, Phil Broadhurst; University Hospital of North Tees (Stockton-on-Tees): Sarah Purvis; Royal Cornwall Hospitals NHS Trust (Truro): Spikey Michael, Warwick Hospital (Warwick); Benjamin Shuker; Royal Hampshire County Hospital (Winchester): Irina Grecu; Queen Elizabeth University Hospital (Woolwich): Daniel Harding; Bassetlaw District General Hospital (Worksop): Natalia Singatullina,

UNITED STATES: University of New Mexico School of Medicine (Albuquerque, NM); James T. Dean, Nathan D. Nielsens, Brooklyn VA Medical Center (Brooklyn, VA); Sama Al-Bayati; SUNY Downstate Medical Center (Brooklyn, NY); Moham‑med Al-Sadawi; Cooper University Hospital (Camden, NJ); Mariane Charron; St. Joseph Hospital (Denver, CO); Peter Stubbenrauch; Ochsner Medical Center (New Orleans, LA); Jairo Santanilla, Katherine Wentworths; University of Utah Health (Salt Lake City, UT); Doroethea Rosenberger, Stony Brook University Hospital (Stony Brook, NY); Polkiseni Eksarlo, Randeep Jawa.

Author contributions
Conceptualisation: ACM, AE, PP, MC, JDw. Methodology: KK, TdC, AE, HjDG, PE. Software: KK, TdC, AE, HjDG, PE. Formal analysis: KK, TdC. Investigation: ACM, AE, PE, PP, RW, DJ, SK, NN, AJ, JDw. Provision of resources: MC, JDw. Data curation: TdC, AE, Cambridge; Chris Hall, Alasdair Jubb; ACM, TdC, JDw. Writing - review and editing: ACM, KK, TdC, AE, PP, PM, DJ, SK, NN, AJ, JDw. Supervision: ACM, MC, JDw. Project administration: MC, JDw. Funding: JDw. All authors read and approved the final manuscript.

Funding
European Society of Intensive Care Medicine. ACM is supported by a Clinician Scientist Fellowship from the Medical Research Council (MRV006118/1).

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. The data curation pipeline and data quality assessment (version 3.1) are publicly available https://doi.org/10.5281/zenodo.6063905

Declarations

Ethics approval and consent to participate
The study received approval from Ghent University Hospital Ethics committee, registration BC-07826 and appropriate approvals at each participating site in line with local regulations. Where required by local regulations consent for inclusion was sought from the patient or their representative, other sites approved consent waiver for use of anonymised, routinely collected data.

Consent to publish
Not applicable: No individual participant data are included.

Competing interests
ACM sits on the scientific advisory board of Cambridge Infection Diagnostics. PP received fees for consulting and lectures to Gilead, Pfizer, MSD and Sanofi. NN has received consulting honoraria from Johnson & Johnson and serves on the scientific advisory board of Adrenomed. The other authors declare that they have no competing interests.

Author details
1 Division of Anaesthesia, Department of Medicine, Level 4 Addenbrooke’s Hospital, University of Cambridge, Hills Road, Cambridge, UK. 2Division of Immunology, Department of Pathology, University of Cambridge, Cambridge, UK. 3Division of Intensive Care Medicine, Ghent University Hospital, Ghent, Belgium. 4Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium. 5Neurocritical Care Unit, Addenbrooke’s Hospital, Cambridge, UK. 6Department of Intensive Care, Amsterdam UMC Location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. 7Laboratory for Critical Care Computational Intelligence, Amsterdam Medical Data Science, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands. 8Nova Medical School, New University, Lisbon, Portugal. 9Center for Clinical Epidemiology and Research Unit of Clinical Epidemiology, OHU Odense University Hospital, Odense, Denmark. 10Polyvalent Intensive Care Unit, Hospital de São Francisco Xavier, CHL9, Lisbon, Portugal. 112Nd Critical Care Department, Attikon University Hospital, University of Athens, Athens, Greece. 1211IQ Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland, Brisbane, Australia. 13Deenanath Mangeshkar Hospital and Research Center, Pune, India. 14Division of Pulmonary, Critical Care and Sleep Medicine and Transfusion Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA. 15Department of Anaesthesia, Humanitas University, Milan, Italy.

Received: 24 June 2022 Accepted: 26 July 2022 Published: 3 August 2022

References
1. Greco M, Corte TD, Ecorle A, et al. Clinical and organizational factors associated with mortality during the peak of first COVID-19 wave: the global UNITEd-COVID study. Intens Care Med. 2022. https://doi.org/10.1007/s00134‑022‑06705‑1
2. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS‑CoV‑2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574‑81.
3. Zhang J, Dong X, Cao Y, et al. Clinical characteristics of 140 patients infected with SARS‑CoV‑2 in Wuhan, China. Allergy. 2020;75(10):1223‑1232.
